We are live on ! Find out more
CRNX icon

Crinetics Pharmaceuticals
CRNX

94 hedge funds and large institutions have $708M invested in Crinetics Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 34 increasing their positions, 20 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

183% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 6

70% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 20

13% more funds holding

Funds holding: 83 → 94 (+11)

7% more capital invested

Capital invested by funds: $661M → $708M (+$47.3M)

0.22% less ownership

Funds ownership: 87.44% → 87.22% (-0.22%)

60% less funds holding in top 10

Funds holding in top 10: 5 → 2 (-3)

Holders
94
Holders Change
+11
Holders Change %
+13.25%
% of All Funds
1.65%
Holding in Top 10
2
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-60%
% of All Funds
0.04%
New
17
Increased
34
Reduced
20
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BI
BVF Inc
California
+$19.4M
2
FM
Frazier Management
Washington
+$17.8M
3
State Street
State Street
Massachusetts
+$11.9M
4
MB
MPM BioImpact
Massachusetts
+$6.24M
5
DCM
Driehaus Capital Management
Illinois
+$6.08M

Top Sellers

Rank Fund Capital Flow
1
VC
Vivo Capital
California
-$25.8M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$14.5M
3
ACM
Altium Capital Management
New York
-$7.11M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
-$5.4M
5
CCM
CAAS Capital Management
New York
-$3.13M
Name Holding Trade Value Shares
Change 		Change in
Stake
ACM
26
Altium Capital Management
New York
$4.06M -$7.11M -340,033 -64%
GTC
27
Ghost Tree Capital
New York
$3.16M -$1.95M -93,309 -38%
Two Sigma Investments
28
Two Sigma Investments
New York
$3.08M +$627K +29,982 +26%
NLVP
29
New Leaf Venture Partners
New York
$2.97M – – –
Two Sigma Advisers
30
Two Sigma Advisers
New York
$2.94M +$1.15M +54,800 +64%
N
31
Nuveen
North Carolina
$2.76M -$571K -27,293 -18%
Deutsche Bank
32
Deutsche Bank
Germany
$1.9M +$20.3K +970 +1%
Russell Investments Group
33
Russell Investments Group
United Kingdom
$1.75M +$1.74M +83,104 New
Morgan Stanley
34
Morgan Stanley
New York
$1.45M -$2.36M -113,043 -62%
T. Rowe Price Associates
35
T. Rowe Price Associates
Maryland
$1.39M +$4.98K +238 +0.4%
Goldman Sachs
36
Goldman Sachs
New York
$1.17M -$113K -5,380 -9%
Swiss National Bank
37
Swiss National Bank
Switzerland
$1.04M – – –
SCM
38
Silverarc Capital Management
Massachusetts
$1.04M +$1.03M +49,382 New
AA
39
ALPS Advisors
Colorado
$999K -$43.5K -2,080 -4%
D.E. Shaw & Co
40
D.E. Shaw & Co
New York
$886K +$227K +10,863 +35%
California State Teachers Retirement System (CalSTRS)
41
California State Teachers Retirement System (CalSTRS)
California
$814K -$245K -11,704 -23%
State of Wisconsin Investment Board
42
State of Wisconsin Investment Board
Wisconsin
$813K – – –
Citadel Advisors
43
Citadel Advisors
Florida
$783K -$490K -23,439 -39%
RhumbLine Advisers
44
RhumbLine Advisers
Massachusetts
$745K +$38.7K +1,852 +6%
AllianceBernstein
45
AllianceBernstein
Tennessee
$621K – – –
TRSOTSOK
46
Teachers Retirement System of the State of Kentucky
Kentucky
$581K +$577K +27,597 New
Rafferty Asset Management
47
Rafferty Asset Management
New York
$579K +$576K +27,513 New
New York State Common Retirement Fund
48
New York State Common Retirement Fund
New York
$555K -$107K -5,135 -16%
Blackstone Inc
49
Blackstone Inc
New York
$512K +$509K +24,334 New
Citigroup
50
Citigroup
New York
$500K +$400K +19,122 +412%
1
2
3 4

CRNX Hedge Fund Activity: Q3 2021 in Review

94 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Crinetics Pharmaceuticals (CRNX) for Q3 2021, worth a combined $708M — up 7.2% from $661M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new CRNX positions and 6 closed out — a net gain of 11 holders — while 34 added to existing stakes and 20 trimmed.

The largest buyer was BVF Inc, adding an estimated $19.4M. The largest seller was Vivo Capital, cutting an estimated $25.8M.

  • 94 institutional investors held Crinetics Pharmaceuticals (CRNX) as of Q3 2021, up from 83 in Q2 2021.
  • Funds reported $708M of Crinetics Pharmaceuticals stock for Q3 2021, up 7.2% quarter-over-quarter.
  • 17 funds opened new Crinetics Pharmaceuticals positions in Q3 2021 and 6 closed out, a net change of +11 holders.
  • The largest Crinetics Pharmaceuticals buyer in Q3 2021 was BVF Inc, an estimated $19.4M added.
  • The largest Crinetics Pharmaceuticals seller in Q3 2021 was Vivo Capital, an estimated $25.8M sold.

Based on aggregated 13F filings for Q3 2021.